A recombinant secondary antibody mimic as a target-specific signal amplifier and an antibody immobilizer in immunoassays

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Min, Junseon ^a,c   Song, Eun Kyung ^a   Kim, Hansol ^a   Kim, Kyoung Taek ^b   Park, Tae Joo ^a   Kang, Sebyung ^a  

^a Ulsan National Institute of Science and Technology   (South Korea)

^b Seoul National University   (South Korea)

^c Duke University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; GLUTATHIONE; GLUTATHIONE TRANSFERASE; HORSERADISH PEROXIDASE; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT;

ANIMAL; BIOSYNTHESIS; CHEMISTRY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; KINETICS; METABOLISM; MOUSE; QUARTZ CRYSTAL MICROBALANCE; RABBIT; RAT; SURFACE PLASMON RESONANCE;

ANIMALS; ANTIBODIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLUTATHIONE; GLUTATHIONE TRANSFERASE; HORSERADISH PEROXIDASE; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOHISTOCHEMISTRY; KINETICS; MICE; QUARTZ CRYSTAL MICROBALANCE TECHNIQUES; RABBITS; RATS; RECOMBINANT FUSION PROTEINS; SURFACE PLASMON RESONANCE;

EID: 84964393697     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep24159     Document Type: Article

References (22)

1. Allen, T. M. Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer 2, 750-763 (2002).
2. Carter, P. Improving the efficacy of antibody-based cancer therapies. Nat. Rev. Cancer 1, 118-129 (2001).
3. Hainfeld, J. F. Uranium-loaded apoferritin with antibodies attached: molecular design for uranium neutron-capture therapy. Proc. Natl. Acad. Sci. USA 89, 11064-11068 (1992).
4. von Mehren, M., Adams, G. P. and Weiner, L. M. Monoclonal antibody therapy for cancer. Ann. Rev. Medicine 54, 343-369 (2003).
5. Danczyk, R. et al. Comparison of antibody functionality using different immobilization methods. Biotechnol. Bioeng. 84, 215-223 (2003).
6. Jung, Y. W. et al. Controlled antibody immobilization onto immunoanalytical platforms by synthetic peptide. Anal. Biochem. 374, 99-105 (2008).
7. Braisted, A. C. and Wells, J. A. Minimizing a binding domain from protein A. Proc. Natl. Acad. Sci. USA 93, 5688-5692 (1996).
8. Deisenhofer, J. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8- A resolution. Biochemistry 20, 2361-2370 (1981).
9. Lee, J. et al. An enhanced ascorbate peroxidase 2/antibody-binding domain fusion protein (APEX2-ABD) as a recombinant targetspecific signal amplifier. Chem. Comm. 51, 10945-10948 (2015).
10. Kang, H. J. et al. Developing an antibody-binding protein cage as a molecular recognition drug modular nanoplatform. Biomaterials 33, 5423-5430 (2012).
11. Moon, H. et al. Fabrication of uniform layer-by-layer assemblies with complementary protein cage nanobuilding blocks via simple His-tag/metal recognition. J. Mater. Chem. B 1, 4504-4510 (2013).
12. Jeong, Y. J., Kang, H. J., Bae, K. H., Kim, M. G. and Chung, S. J. Efficient selection of IgG Fc domain-binding peptides fused to fluorescent protein using E. coli expression system and dot-blotting assay. Peptides 31, 202-206 (2010).
13. Bobrow, M. N., Harris, T. D., Shaughnessy, K. J. and Litt, G. J. Catalyzed reporter deposition, a novel method of signal amplification application to immunoassays. J. Immunol. Methods 125, 279-285 (1989).
14. Butler, J. E. Enzyme-Linked Immunosorbent Assay. J. Immunoassay 21, 165-209 (2000).
15. Gijlswijk, R. P. M. V. et al. Fluorochrome-labeled Tyramides: Use in Immunocytochemistry and Fluorescence In Situ Hybridization. J. Histochem. and Cytochem. 45, 375-382 (1997).
16. Bobrow, M. N., Litt, G. J., Shaughnessy, K. J., Mayer, P. C. and Conlon, J. The use of catalyzed reporter deposition as a means of signal amplification in a variety of formats. J. Immunol. Methods 150, 145-149 (1992).
17. Spizzo, G. et al. Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol. Oncol. 103, 483-488 (2006).
18. Went, P. et al. Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br. J. Cancer 94, 128-135 (2006).
19. Kieserman, E. K., Lee, C., Gray, R. S., Park, T. J. and Wallingford, J. B. High-Magnification In Vivo Imaging of Xenopus Embryos for Cell and Developmental Biology. CSH protocols 5, doi: 10.1101/pdb.prot5427 (2010).
20. Lee, C., Kieserman, E., Gray, R. S., Park, T. J. and Wallingford, J. Whole-mount fluorescence immunocytochemistry on Xenopus embryos. CSH protocols 3, doi: 10.1101/pdb.prot4957 (2008).
21. Nieuwkoop, P. D. and Faber, J. Normal table of Xenopus laevis (Daudin) : a systematical and chronological survey of the development from the fertilized egg till the end of metamorphosis. (Garland Pub., 1994).
22. Moon, H., Lee, J., Min, J. and Kang, S. Developing Genetically Engineered Encapsulin Protein Cage Nanoparticles as a Targeted Delivery Nanoplatform. Biomacromolecules 15, 3794-3801 (2014).